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a b s t r a c t
Rabbit antithymocyte globulin (Thymoglobulins) is commonly used as graft-versus-host disease (GvHD)
prophylaxis. Since we found similar total CD8 T cell numbers in patients with and without Thymoglo-
bulins therapy within the first six months after allogeneic hematopoietic stem cell transplantation, we
have analyzed the reconstitution of the CD8 T cell compartment in detail. After T cell-depletion, higher
and more sustained proliferative capacity of memory CD8 T cells resulted in their rapid expansion,
whereas the fraction of naive CD8 T cells decreased. Importantly, this shift towards effector memory CD8
T cells did not accelerate the incidence of GvHD.
& 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
1. Introduction
One of the major complications associated with allogeneic
hematopoietic stem cell transplantation (alloHSCT) is the high
incidence of acute graft-versus-host disease (GvHD) caused by
donor T-lymphocytes. Depletion of donor T-lymphocytes is a well-
established therapeutic option for GvHD-prophylaxis. Recently, we
showed a sustained depletion of conventional and regulatory CD4
T cells in patients treated with ATG-Genzyme™ (Thymoglobulins,
ATG-G) [1], a polyclonal antibody preparation containing a broad
spectrum of antibodies directed against T cells [2] and potentially
thymic stromal cells. Interestingly, total CD8 T cell counts were
similar in ATG-G treated and untreated patients[1]. In principle,
T cell recovery after transplantation can take place through thymus
dependent regeneration as well as by proliferation of existing
T cells [3].
Here, we addressed whether the rapid CD8 T cell recovery after
ATG-G depletion resulted from accelerated CD8 T cell regeneration
or increased peripheral CD8 T cell proliferation and in how far this
influenced GvHD incidence. Therefore, we studied the distribution
of different CD8 T cell subsets and their proliferative capacity in
ATG-G treated patients of the same patient cohort.
2. Material and methods
A detailed description of methods and patient cohorts can be
found in Na et al. [1] (approval by the Charité – Berlin local ethics
committee no. EA4/128/09). Briefly, we compared CD8 T cell
reconstitution in 12 alloHSCT patients receiving ATG-G according
to standard procedure protocols (ATG-G group, for dþ180: n¼11)
with 8 alloHSCT patients not receiving ATG-G (noATG-G group, for
dþ180: n¼3). Patient characteristics and clinical outcome are
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presented in Table 1. Indications for transplantation were hema-
tologic malignancies in all cases (AML n¼17, ALL n¼2, CLL n¼1).
Patients received ATG-G additionally to standard conditioning
regimens if transplanted with grafts from matched-unrelated
donors (MUD) as opposed to matched related donors (MRD) in
the noATG-G group. One patient receiving an MUD graft did not
receive ATG-G.
Multicolor flow cytometry (Becton Dickinson LSRII supported
by FlowJo 9.3 software, TreeStar) was used to identify different
CD8 T cell subsets after standard staining procedures of peripheral
blood mononuclear cells (PBMC) from fresh heparinized blood
samples. The following antibodies were used to characterize the
CD8 T cell subsets: anti-CD3 APC/Cy7 (clone UCHT1; BioLegend),
anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend), anti-CD8
V500 (clone RPA-T8; BD Biosciences), anti-CD45RA PerCP/Cy5.5
(clone HI100; BioLegend), anti-CD45RO Pacific Blue (clone UCHL1;
BioLegend), and anti-CD197 (CCR7) Alexa Fluor 488 (clone TG8/
CCR7; BioLegend). For evaluation of Ki67 expression stainings
were performed using anti-CD3 APC/Cy7 (clone UCHT1; Bio-
Legend), anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend),
anti-CD8 V500 (clone RPA-T8; BD Horizon), anti-CD45RA
eFlour605 (clone HI100; eBioscience) and anti-Ki67 FITC (clone
B56, BD Pharmingen). CD3 T cell counts were obtained by staining
whole blood samples with CD3-Cy5 (clone UCTH-1, DRFZ, Berlin)
and using BD TruCountTM controls (BD Biosciences). For group
comparisons the Mann-Whitney-U test was used (GraphPad Soft-
ware, La Jolla, CA).
3. Results
Analysis of the CD3 T cell compartment revealed comparable
cell counts in both groups except day 15 after transplantation with
significantly lower absolute counts in the ATG-G group (Fig. 1A;
46.29 cells/μl711.61 (SEM) versus 365.1 cells/μl7102.8 (SEM),
po0.005). The share of CD8þ T cells was significantly higher in
the ATG-G group at all time points post transplantation except
dþ180 (Fig. 1B). On day 15 we observed high rates of CD8 T cell
proliferation only in the ATG-G group, as shown by Ki67 staining
(Fig. 1C,D; 49.0%76.8% in ATG-G group versus 11.0%72.6% in
noATG-G group on dþ15, po0.01). We then compared prolifera-
tive activity of CD45RAþ and CD45RA CD8 T cells within the
ATG-G group. Proliferation rates of CD45RA CD8 T cell subsets
were higher at all time points after transplantation as compared to
CD45RAþ CD8 T cell subsets with significant differences on days
60, 90 and 180 (Fig. 1E,F). At day 15 CD45RAþ CD8 T cells also
showed a strikingly high proportion of Ki67þ cells (35.1%77.7%).
However, at day 30 this share dropped (3.2%70.9%) and
remained low.
Next, we used a gating strategy originally suggested by Sallusto
et al. [4] to assess naive (CD45RAþCCR7þ), central memory (CM,
CD45RACCR7þ), effector memory (EM, CD45RACCR7) and
effector (CD45RAþCCR7) CD8 T cells (Fig. 2A). We observed
significantly higher frequencies of EM CD8 T cells in the ATG-G
group at all time points except dþ180 (Fig. 2B). In contrast,
frequencies of naive CD8 T cells were significantly lower in ATG-
G treated patients compared to patients without ATG-G treatment
at all time points post transplantation (Fig. 2C). The frequencies of
CM and effector CD8 T cells were comparable in both groups
(Fig. 2D, E).
4. Discussion
Investigating the impact of ATG-G as a T cell depleting strategy
[2], as expected we observed lower CD3 T cell counts in the ATG-G
group. Considering the half-life of ATG-G (clearance to sub-
therapeutic levels by a median of 1779 days [5]), unsurprisingly
there was only a significant difference of CD3 T cell counts early
after alloHSCT. The observed persistent increase of CD8 T cell
frequencies is likely to be mainly due to decreased CD4 T cell
counts as previously described [1].
Table 1
Patient characteristics and clinical outcome.
Patient
no.
Age a(years) Diagnosis Donor Conditioning
regimen
Deceased b Leukocyte
engraftment c
Grade of
aGVHD
ATG-G group 1 50 AML MUD Cy/TBI dþ15 I
2 mg/kg/day on days 3,2,1 before
transplantation
2 27 AML MUD Cy/TBI dþ18 III
3 28 ALL MUD Cy/TBI dþ15 I
4 48 AML MUD Cy/TBI x dþ12 I
5 57 ALL MUD Cy/TBI dþ13 III
6 58 AML MUD Fludara/Treo dþ16 I
7 50 AML MUD Cy/TBI dþ14 None
8 69 AML MUD FLAMSA dþ13 II
9 60 AML MUD Fludara/Treo dþ16 I
10 47 AML MUD Cy/TBI dþ13 None
11 57 AML MUD Fludara/8 Gy TBI dþ17 None
12 48 AML MUD Cy/TBI dþ13 I
noATG-G group 13 58 AML MRD Fludara/Treo dþ15 II
14 41 AML MRD FLAMSA x dþ8 None
15 34 AML MRD Cy/TBI x dþ17 None
16 57 AML MRD Cy/TBI x dþ15 II
17 40 AML MUD Bu/Cy x dþ30 III
18 61 AML MRD MitoFLAG x dþ17 I
19 57 AML MRD Fludara/Treo dþ19 II
20 67 CLL MRD Fludara/2 Gy TBI dþ17 II
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphatic leukemia; Bu, busulfane; CLL, chronic lymphatic leukemia; Cy, cyclophosphamide; FLAMSA, Fludarabin,
Cytosin-Arabinosid and Amsacrin; Fludara, fludarabine; aGvHD, acute graft-versus-host disease; Gy, Gray; MitoFLAG, Mitoxantrone, Fludarabine, Cytosin-Arabinosid and
granulocyte-colony stimulating factor; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation; Treo, treosulfane.
a Age at transplantation.
b Deceased between days þ90 and þ180 after transplantation.
c Time to leukocyte engraftment in days after transplantation.
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Analysis of the CD8 T cell compartment in detail revealed a shift
towards high EM and low naive CD8 T cell frequencies in the
ATG-G group. This shift was observed up to dþ180 after alloHSCT,
suggesting indirect long-term effects resulting from ATG-G treat-
ment. Low shares of naive CD8 T cells could be the consequence of
a rapid transition into the memory pool or thymic impairment due
to ATG-G as previously suggested for CD4 T cell regeneration [1].
The rapid increase of EM CD8 T cells appears to be driven mainly
by homeostatic mechanisms in the ATG-G depleted host, since
concomitant high rates of CD8 T cell proliferation were found
around day 15 in the ATG-G group only. This hypothesis is
supported by consistently higher proliferation rates of CD45RA
CD8 T cells as compared to CD45RAþ CD8 T cells within the ATG-G
group. However, it has previously been shown that changes
towards an EM phenotype from other subsets such as naive CD8
T cells are also induced by T cell receptor stimulation and that CM
CD8 T cells undergo various phenotypic changes upon cytokine
stimulation, amongst others towards an EM phenotype [6]. It
cannot be excluded that both these mechanisms contribute to
the expansion of the EM CD8 T cell subset. Yet, the same reports
also support the notion that EM CD8 T cells are especially receptive
to cytokine stimulation [6] thus favoring the hypothesis of homeo-
static proliferation.
In line with larger clinical studies demonstrating ATG-G effi-
cacy especially for prevention of severe acute GvHD (reviewed in
[7]), acute GvHD-rates in both patient groups in our study were
similar even though ATG-G treated patients were transplanted
with MUD grafts as opposed to MRD grafts in the noATG-G group
and thus were at higher risk of GvHD (acute GvHD ATG-G group
versus noATG-G group: Grade I and II 58% versus 63%, Grade III
and IV 17% versus 13%). Consequently, the initial T cell depletion by
ATG-G limited GvHD in MUD transplantations as intended. Yet,
this also suggests that the significant expansion of EM CD8 T cells
in the ATG-G group is not driving GvHD. Results from mouse
studies equally suggest that memory CD8 T cells are less potent in
mediating acute GvHD than naive CD8 T cells [8]. EM CD8 T cells
appear to be favorable over CM CD8 T cells in this respect in mice
[9,10]. Likewise, in vitro studies with human material from healthy
Fig. 1. Proliferative capacity of CD8 T cells after alloHSCT. Mean values of (A) CD3 T cell counts (cells/μl7standard error of mean (SEM)) and (B) CD8 T cell frequencies
(%7SEM) are shown. Proliferation of total (C, D) and CD45RAþ and RA- (E, F; ATG-G group only) CD8 T cells was measured by Ki67 analysis. For statistical evaluation the
Mann Whitney U test was used. npo0.05; nnpo0.01; nnnpo0.005.
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donors indicate an increased alloreactivity of naive CD8 T cells as
compared to memory CD8 T cells under certain conditions [11].
In summary, our data suggest that rapid recovery of CD8 T cells
after ATG-G induced T cell depletion in alloHSCT patients is due to
peripheral homeostatic proliferation of EM CD8 T cells and not due
to accelerated regeneration of naive CD8 T cells. This leads to a
characteristic shift to EM CD8 T cells that is not associated with
higher rates of GvHD.
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